[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"masldmash-metabolic-dysfunction-associated-steatotic-liver-disease--metabolic-dysfunction-associated-steatohepatitis\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:masldmash-metabolic-dysfunction-associated-steatotic-liver-disease--metabolic-dysfunction-associated-steatohepatitis":25},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,6,0,[8,44,70,97,127,157],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":23,"conditions":24,"keywords":26,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":32,"lastUpdatePostDateStruct":33,"startDateStruct":36,"completionDateStruct":38,"leadSponsor":40,"locationsCount":43},"100618377","study-of-pnpla3-genetic-polymorphisms-in-patients-with-non-alcoholic-fatty-liver-disease-in-an-ultramarine-population-adipodromexpo-100618377",false,"NCT07330830","Study of PNPLA3 Genetic Polymorphisms in Patients With Non-Alcoholic Fatty Liver Disease in an Ultramarine Population (AdipoDROMExpo)","Study of PNPLA3 Genetic Polymorphisms in Patients With Non-Alcoholic Fatty Liver Disease in an Ultramarine Population","AdipoDROMExpo","IInclusion Criteria\n\n-Adult patients (≥18 years old) seen in consultation or hospitalized in the Hepato-Gastroenterology Departments of the University Hospitals of Guadeloupe, French Guiana, and Réunion Island, with a diagnosis of MASLD.\n\nMASLD is defined as evidence of hepatic steatosis associated with overweight\u002Fobesity, type 2 diabetes, or metabolic syndrome according to ATP III (2005) criteria.\n\n* Patients affiliated with, or beneficiaries of, a social security scheme.\n* Free, informed, and written consent obtained from the participant and signed by both the participant and the investigator (no later than the day of inclusion and prior to any procedure required by the study).\n\nExclusion Criteria:\n\n* Patients under 18 years of age.\n* Patients unable to provide informed consent; so-called vulnerable populations (individuals under guardianship, judicial protection, etc.).\n* Presence of another cause of chronic liver disease, including:\n\nViral hepatitis (B, C, or E)\n\nPrimary biliary cholangitis or primary sclerosing cholangitis\n\nAutoimmune hepatitis\n\nWilson's disease\n\nHemochromatosis\n\nAlpha-1 antitrypsin deficiency\n\nAlcoholic liver disease, or daily alcohol consumption \\>30 g\u002Fday for men or \\>20 g\u002Fday for women\n\n-Pregnant women.","ALL","18 Years",{"count":20,"type":21},600,"ESTIMATED","OBSERVATIONAL","Metabolic Dysfunction Associated Liver Disease (MASLD) is associated with metabolic syndrome, and PNPLA3 variants are known to be implicated in intrahepatic lipid accumulation and linked to lipotoxicity. Analysis of PNPLA3 polymorphisms in an overseas territories population of MASLD would be interesting to describe their profile susceptibility to develop Metabolic dysfunction associated steatohepatitis (MASH).",[25],"MASLD\u002FMASH (Metabolic Dysfunction-Associated Steatotic Liver Disease \u002F Metabolic Dysfunction-Associated Steatohepatitis)",[27,28,29,30],"MASLD","MASH","PNPLA3","genetic polymorphism","RECRUITING","2026-01-05",{"date":34,"type":35},"2026-01-09","ACTUAL",{"date":37,"type":35},"2025-11-26",{"date":39,"type":21},"2027-11-28",{"name":41,"class":42},"Centre Hospitalier Universitaire de la Guadeloupe","OTHER",3,{"id":45,"slug":46,"hasResults":11,"nctId":47,"briefTitle":48,"officialTitle":49,"acronym":4,"eligibilityCriteria":50,"healthyVolunteers":51,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":52,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":54,"conditions":55,"keywords":57,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":32,"lastUpdatePostDateStruct":60,"startDateStruct":62,"completionDateStruct":64,"leadSponsor":66,"locationsCount":69},"100617692","thermoacoustic-method-for-estimating-liver-fat-fraction-100617692","NCT07321925","Thermoacoustic Method for Estimating Liver Fat Fraction","Thermoacoustic Method for Estimating Liver Fat Fraction - Pilot Study I","Inclusion Criteria:\n\n* Study participants are 18 or older.\n* Able to understand, read, and provide written informed consent in English.\n* Able to tolerate both ultrasound and MRI examinations.\n* Able to lie flat, or on their side, for 20 minutes and pause breathing for up to 10 seconds.\n\nExclusion Criteria:\n\n* Metal or electronic implants, including, but not limited to: pacemakers, metal clips, drug delivery pumps, hip implants, and neural stimulation devices, contraindicates for MRI.\n* Known pregnancy the day of consent or becoming pregnant during study participation based on start date of last menstrual period).\n* Liver diseases other than MASLD\u002FMASH\u002Ffibrosis including, but not limited to:\n* Cirrhosis\n* Hepatocellular carcinoma\n* Ascites\n* Patients with broken, or injured skin, in the right upper abdominal quadrant.\n* Body habitus, or anatomical variation, where the liver capsule is not accessible with ultrasound through the patient's right intercostal imaging window used in conventional ultrasound liver imaging.\n* BMI greater than 50 kg\u002Fm2\n* Patients with subcutaneous fat at measurement location less than or equal to 6mm.\n* Patients with a missing liver lobe.\n* Patients with peri-hepatic fat in the measurement location.\n* Patients with focal liver lesions or anatomical structures in the measurement location, as detected by ultrasound.",true,{"count":53,"type":21},49,"The goal of this study is to use our Thermoacoustic Enhanced Ultrasound device to measure the fat levels in your liver and compare it to the the gold standard MRI PDFF measurements. Participants will have a scan with our device, then they will go have an abdominal MRI completed. The goal is to create a more accessible device to measure liver fat as it is an indicator for overall health and metabolic diseases.",[25,56],"Fatty Liver Disease, Nonalcoholic",[58,27,28,59],"Fatty Liver","Thermoacoustic",{"date":61,"type":35},"2026-01-07",{"date":63,"type":35},"2025-08-15",{"date":65,"type":21},"2025-12-31",{"name":67,"class":68},"Endra Lifesciences","INDUSTRY",1,{"id":71,"slug":72,"hasResults":11,"nctId":73,"briefTitle":74,"officialTitle":74,"acronym":75,"eligibilityCriteria":76,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":77,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":79,"conditions":80,"keywords":83,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":88,"lastUpdatePostDateStruct":89,"startDateStruct":91,"completionDateStruct":93,"leadSponsor":95,"locationsCount":69},"100614480","the-development-of-masld-among-survivors-of-breast-or-colorectal-cancer-100614480","NCT07280143","The Development of MASLD Among Survivors of Breast or Colorectal Cancer","EVALUATE","Inclusion criteria:\n\n* Signed Informed consent form\n* Age ≥ 18 years\n* Diagnosis of BC or CRC at least 5 years but no more than 10 years before enrollment, and no recurrence or new cancer diagnoses during this time period (except for superficial non-melanoma skin cancer or superficial bladder cancer or cancer in-situ). Patients who received\u002Fare still receiving adjuvant therapy may be included. Time period is calculated from date of first histological diagnosis of cancer.\n\nExclusion criteria:\n\n* Known or suspected chronic hepatic disease\n* Pregnancy, or suspected pregnancy (as liver stiffness and fat content are often elevated but reverse after childbirth)\n* For the MRI sub-study: Contraindication to MRI, including: claustrophobia and presence of metal implants or devices or foreign metal objects in\u002Fon the body, such as pacemakers, defibrillators, prosthetic cardiac valves, cochlear implants, metal clips e.g., vascular clips, spinal cord stimulators or deep brain stimulators, shrapnel or bullet fragments, metal in the eyes, orthopedic hardware and piercings that cannot be easily removed.",{"count":78,"type":21},200,"A metabolic issue is a condition where the body has problems with converting food into energy, using energy or storing energy properly. Examples of metabolic issues include obesity, diabetes, or high blood pressure\n\nMASLD -Metabolic-associated steatotic liver disease - also known as non-alcoholic fatty liver disease, is a condition where fat builds up in the liver due to metabolic issues. Excess liver fat can cause inflammation, scaring, also known as fibrosis, and over time, lead to liver failure.\n\nMASLD can have different severities. Non-fibrotic MASLD is when there is a small amount of fat in the liver and usually does not cause major problems. However, it can get worse over time and can develop into fibrotic MASLD.\n\nMASLD is very common, about one-third of the world's population is affected. In Switzerland, it is predicted that one-quarter of the Swiss population is affected by it. MASLD can affect anyone who has any metabolic issues, however it seems like some medications, such as cancer treatments, could play a role in MASLD development.\n\nStudying MASLD is important because it is very common. Learning more about it can help doctors find better ways to diagnose and treat the condition.\n\nFurthermore, it is important to find out who would be more likely to develop MASLD. People who are more likely could maybe do some regular testing to diagnose it early and start treatment before it is worsening. Early diagnosis is important since liver damage can be reversed with lifestyle changes, diet or medication.\n\nCancer survivors are at a higher risk of developing MASLD due to changes in their metabolism, lifestyle as well as side effects of cancer treatments. However, MASLD is often underdiagnosed in cancer survivors, even though it can increase the risk of future health complications.\n\nCurrently, liver biopsy is the standard method of diagnosing MASLD, as it provides the most accurate results. However, liver biopsy is uncomfortable and carries risks like pain and infections.\n\nNewer non-invasive technologies, such as ultrasound-based vibration-controlled transient elastography (VCTE, also known as FibroScan®) and Magnetic Resonance Imaging (MRI), show promise in detecting liver fibrosis earlier and more safely. However, they are not yet widely used because they are not as precise as biopsy at detecting liver inflammation.\n\nEVALUATE is an observational study performed by the Department of Clinical Research at the University of Bern. In collaboration with the Department of Hepatology, Inselspital, University Hospital of Bern and the Department of Radiology, University Cancer Centre Inselspital.\n\nEVALUATE will use two of the newer, less painful methods - VCTE and MRI to check for signs of fibrotic MASLD. Combined with a blood test, a score can be calculated to see if someone is at high-risk for advanced MASLD.\n\nIn the case that the results from the main study are uncertain, the participant will be asked to participate in an MRI sub study.\n\nThis study will help improve ways to check for liver disease in cancer survivors, leading to early detection and quicker treatment. Eventually the information of this study could help create better guidelines and improve care for cancer survivors at risk of liver problems.",[81,82,25],"Breast Cancer Survivors","Colorectal (Colon or Rectal) Cancer Survivors",[27,84,85,86,87],"Cancer survivorship","Survivorship care","Non-invasive imaging","Liver fibrosis screening","2025-12-01",{"date":90,"type":35},"2025-12-12",{"date":92,"type":35},"2025-11-14",{"date":94,"type":21},"2027-11-30",{"name":96,"class":42},"University of Bern",{"id":98,"slug":99,"hasResults":11,"nctId":100,"briefTitle":101,"officialTitle":102,"acronym":4,"eligibilityCriteria":103,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":104,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":106,"conditions":107,"keywords":113,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":119,"lastUpdatePostDateStruct":120,"startDateStruct":122,"completionDateStruct":124,"leadSponsor":125,"locationsCount":69},"100598351","digital-early-warning-system-for-acute-lung-injury-in-liver-surgery-100598351","NCT07070362","Digital Early Warning System for Acute Lung Injury in Liver Surgery","The Construction of a Digital Intelligence Early Warning System for the Whole Process of Acute Lung Injury in Liver Surgery Based on Cardiopulmonary Interaction Characteristics","Inclusion Criteria:\n\n* Age ≥ 18 years\n* Undergoing major liver surgery (including two-segment or more hepatectomy, liver transplantation, etc.)\n* Voluntary participation with signed informed consent",{"count":105,"type":21},4000,"This study focuses on developing an explainable machine learning model based on cardiopulmonary interaction characteristics to achieve early prediction of acute lung injury (ALI) in patients undergoing major liver surgery. The research will establish a digital early-warning system for ALI to provide support for clinical diagnosis and treatment decisions, thereby reducing the incidence and fatality rate of ALI.",[108,109,110,27,25,111,112],"Acute Lung Injury(ALI)","Liver Cirrhosis","ARDS, Human","NAFLD (Nonalcoholic Fatty Liver Disease)","Liver Cancer, Adult",[114,115,116,117,118],"Digital Intelligence","Acute Lung Injury","PPCs","Liver Surgery","Cardiopulmonary Interaction;","2025-07-08",{"date":121,"type":35},"2025-07-17",{"date":123,"type":35},"2024-11-01",{"date":94,"type":21},{"name":126,"class":42},"Beijing Tsinghua Chang Gung Hospital",{"id":128,"slug":129,"hasResults":11,"nctId":130,"briefTitle":131,"officialTitle":132,"acronym":4,"eligibilityCriteria":133,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":134,"enrollmentInfo":135,"targetDuration":4,"studyType":137,"phases":138,"briefSummary":140,"conditions":141,"keywords":145,"overallStatus":147,"whyStopped":4,"lastUpdateSubmitDate":148,"lastUpdatePostDateStruct":149,"startDateStruct":151,"completionDateStruct":153,"leadSponsor":155,"locationsCount":69},"100594940","phase-2-effect-of-sinbiotic-with-multispecies-probiotics-on-liver-parameters-liver-enzymes-ultrasound-elastography-and-adipokines-in-same-cases-in-patients-with-metabolic-associated-steatotic-liver-disease-100594940","NCT07025980","Effect of Sinbiotic With Multispecies Probiotics on Liver Parameters Liver Enzymes, Ultrasound, Elastography and Adipokines in Same Cases) in Patients With Metabolic Associated Steatotic Liver Disease.","Effect of Sinbiotic With Multispecies Probiotics on Liver Parameters in Patients With Metabolic Associated Steatotic Liver Disease","Inclusion Criteria:\n\n* MASLD confirmed by ultrasound and elastography with CAP \\> 260 dB\u002Fm\u002FMHz;\n* other causes of chronic liver disease excluded and\u002For diagnosis confirmed by liver biopsy,\n* presence of metabolic syndrome according to the definition of the International Diabetes Federation (IDF): waist circumference for women over 80 cm or over 94 cm for men, and at least two of the other criteria (treated hypertensive or blood pressure \\> 130\u002F85 mmHg determined during inclusion; treated diabetic or newly detected fasting serum glucose levels \\> 5.6 mmol\u002Fl; treated dyslipidemia or newly detected serum triglyceride levels \\> 1.7 mmol\u002FL or HDL \\\u003C 1.29 mmol\u002FL for women\u002F\\\u003C 1.03 mmol\u002FL for men),\n* signed informed consent.\n\nExclusion Criteria:\n\n* pregnancy,\n* significant alcohol intake (\\>30g\u002Fday in men, \\>20g\u002Fday in women),\n* presence of autoimmune, viral, cholestatic (primary biliary cholangitis, primary sclerosing cholangitis, obstructive biliary tree diseases) or metabolic (hemochromatosis, Wilson) causes of chronic liver disease, transplant patients, malignant diseases, free fluid in the abdomen, significant small bowel resections,\n* signs of liver cirrhosis or LSM\\>13 kPa measured TE,\n* use of medications that can promote the development of steatosis (e.g. corticosteroids, high doses of estrogen, methotrexate, amiodarone, valproate), and medications that can affect the composition of the microbiota for at least 3 months before the start of the study (antibiotics and probiotics),\n* inability to reliably measure CAP and LSM (IQR\u002Fmedian\\>30%),\n* severe psychiatric patients in whom cooperation and consent are questionable.","75 Years",{"count":136,"type":21},114,"INTERVENTIONAL",[139],"PHASE2","Scientific hypothesis: the use of a synbiotic preparation with a multi-strain probiotic in patients with MASLD can lead to a decrease in non-invasive elastographic parameters of hepatic steatosis and fibrosis and an improvement in liver function.\n\nThe main objective of this study is to examine whether the test product affects the improvement of liver function measured by elastographic parameters or at least the prevention of further disease progression.\n\nThe goal of this clinical trial is to learn if sinbiotics works to improve liver function in adult patients with MASLD The main questions it aims to answer are:\n\nDoes sinbiotic lowers elastographic parameters od steatosis and fibrosis? Does it change liver function by lowering liver enzymes, blood lipids and sugar? Can sinbiotics lower CV risks and improve quality of life? Researchers will compare sinbiotic to a placebo (a look-alike substance that contains no drug) to see if sinbiotic works in MASLD patients.\n\nParticipants will:\n\nTake sinbiotic or a placebo every day (td) for 9 months Visit the clinic once every 3 months for checkups, and at the begining and after 9 months for blood tests and US with elastography Keep a diary of their symptoms, diet, activity",[25,142,143,144],"Diabetes Mellitus","Hypertension","Hyperlipidaemia",[146],"elastography; human LRG1, liver enzymes, metabolic- dysfuncion steatotic liver disease, metabolic syndrome; probiotics, treatment","NOT_YET_RECRUITING","2025-06-10",{"date":150,"type":35},"2025-06-18",{"date":152,"type":21},"2025-07-01",{"date":154,"type":21},"2029-07-31",{"name":156,"class":42},"Eva Cubric",{"id":158,"slug":159,"hasResults":11,"nctId":160,"briefTitle":161,"officialTitle":161,"acronym":162,"eligibilityCriteria":163,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":164,"targetDuration":166,"studyType":22,"phases":4,"briefSummary":167,"conditions":168,"keywords":172,"overallStatus":147,"whyStopped":4,"lastUpdateSubmitDate":179,"lastUpdatePostDateStruct":180,"startDateStruct":182,"completionDateStruct":184,"leadSponsor":186,"locationsCount":188},"100585837","long-term-follow-up-to-determine-outcome-in-liver-disease-love-study-100585837","NCT06907563","Long-term Follow-up to Determine Outcome in Liver Disease (LOVE Study)","LOVE","Inclusion Criteria:\n\n* Previous Informed consent for cohort studies\n* \\> 18 years of age\n* Diagnosis of SLD (MASLD, MetALD, ALD)\n\nExclusion Criteria:\n\n* No consent for previous cohort studies\n* \\\u003C 18 years of age\n* No Diagnosis of SLD (MASLD, MetALD, ALD)",{"count":165,"type":21},30000,"10 Years","The rational to conduct the LOVE study builds on the lack of available data on outcomes in steatotic liver disease in well characterized patients over a time frame of several years. At current limited data on liver-specific and overall outcome in patients with MASLD, MetALD and ALD are available. Liver histology is the only accepted surrogate to reasonably likely predict outcomes in patients with non-cirrhotic liver disease and is currently used in regulatory trials. To overcome the limitations of liver biopsy and use validated non-invasive tests (NITs) to predict outcomes, the LOVE study will be conducted based on existing cohort studies in well pheno- and genotyped patients and will inform on the relevant outcomes based on baseline and ongoing biomarker assessment. The overarching goal is to qualify a NIT for patient identification and preventive measures in the regulatory context.",[169,25,170,171],"Steatotic Liver Disease","Steatotic Liver Disease of Mixed Origin (MetALD)","ALD - Alcoholic Liver Disease",[28,173,174,27,175,176,177,178],"SLD","NITs","ALD","MetALD","Metabolism","Liver","2025-03-26",{"date":181,"type":35},"2025-04-02",{"date":183,"type":21},"2025-04-15",{"date":185,"type":21},"2035-12-31",{"name":187,"class":42},"Universität des Saarlandes",4]